Curus Medical – a biotechnology and biopharmaceutical company based in Sydney
Derived from “Cure Us”, Curus Medical is patient focused and clinically research driven and developing therapeutics for patients with unmet medical conditions and diseases.
Curus Medical is a pioneer in the Australian medicinal cannabis sector to garner much needed research data – its founder secured among the earliest licenses granted by the Office of Drugs Control for medicinal cannabis in Australia.
Curus’ expertise instigated and developed a clinical study to provide new therapeutics for children and adolescents with drug resistant epilepsy.
The study is a global first, a Phase 2a Double-blind, Placebo-controlled Study Investigating the Safety, Tolerability, Efficacy and Pharmacokinetics of a Cannabidiol based product, in Children and Adolescents with Medication Resistant, Refractory Epilepsy. The study has achieved human ethics committee approval.
Curus instigated a pre-clinical study of cannabinoids in a novel strategy for treatment of patients with melanoma cancer.
Curus is also in research identifying novel enzymes that have therapeutic and diagnostic development potential for patients with solid tumour cancers.